Skip to search formSkip to main contentSkip to account menu

maraviroc

Known as: 4,4-difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide, maraviroc [Chemical/Ingredient] 
A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

CCR5 Receptor AntagonistsCyclohexanesTriazoles

Narrower (1)

UK-427,857
maraviroc 300 MG Oral Tablet [Selzentry]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-Human Immunodeficiency Virus Drug Maraviroc
Maraviroc is an anti-human immunodeficiency virus drug that acts by blocking viral entry into target cells. With use of ultra… 
Review
2011
Review
2011
Efficacy of new antiretroviral drugs in treatment‐experienced HIV‐infected patients: a systematic review and meta‐analysis of recent randomized controlled trials
We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) to assess the overall efficacy of new… 
2011
2011
HIV-1 group N: travelling beyond Cameroon
Highly Cited
2010
Highly Cited
2010
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies
Background:The MOTIVATE-1 and 2 studies compared maraviroc (MVC) along with optimized background therapy (OBT) vs. placebo along… 
Review
2010
Review
2010
Treatment of HIV infection with the CCR5 antagonist maraviroc
Importance of the field: The emergence of resistance in treatment-experienced HIV patients often limits therapeutic success of… 
Review
2009
Review
2009
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has… 
Review
2008
Review
2008
Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen
Brass AL, Dykxhoorn DM, Benita Y, et al. Science. 2008;319(5865):921–926 PURPOSE OF THE STUDY. The HIV genome encodes only 15… 
Review
2008
Review
2008
Optimal use of maraviroc in clinical practice.
Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent… 
2008
2008
Post‐exposure prophylaxis with a maraviroc‐containing regimen after occupational exposure to a multi‐resistant HIV‐infected source person
We report the case of a health care worker who received a post‐exposure prophylaxis including an investigational drug, maraviroc… 
2007
2007
Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)